LevyJHTanakaKA. Inflammatory response to cardiopulmonary bypass. Ann.Thorac.Surg.2003; 75: S715–S720.
2.
RoystonDBidstrupBPTaylorKMSapsfordRN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet1987; 2: 1289–91.
3.
RoystonD. High-dose aprotinin therapy: a review of the first five years' experience. J.Cardiothorac.Vasc.Anesth.1992; 6: 76–100.
4.
DietrichWSpannaglMJochumMWendtPSchrammWBarankayAInfluence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology1990; 73: 1119–26.
5.
DietrichWSchopfKSpannaglMJochumMBraunSLMeisnerH. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations. Ann.Thorac.Surg.1998; 65: 70–7.
6.
TanakaKASzlamFKatoriNVegaJDLevyJH. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb.Res.2004; 113: 333–9.
7.
RitchieBC. Protease inhibitors in the treatment of hereditary angioedema. Transfus.Apher.Sci.2003; 29: 259–67.
VigSChitolieABevanDHHallidayADormandyJ. Thromboelastography: a reliable test?Blood Coagul.Fibrinolysis2001; 12: 555–61.
13.
Bennett-GuerreroEBarclayGRYoussefMEHossainSVela-CantosFAndresLAExposure to bacteroides fragilis endotoxin during cardiac surgery. Anesth.Analg.2000; 90: 819–23.
14.
AvidanMSAlcockELDa FonsecaJPonteJDesaiJBDespotisGJComparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br.J.Anaesth.2004; 92: 178–86.
15.
ChalkiadisGAGibbsNM. The effect of aprotinin on thrombelastography in vitro. Anaesth. Intensive Care1996; 24: 552–4.
16.
AvidanMSDa FonsecaJParmarKAlcockEPonteJHuntBJ. The effects of aprotinin on thromboelastography with three different activators. Anesthesiology2001; 95: 1169–74.
17.
GallimoreMJJonesDWWendelHP. Achromogenic substrate assay kit for factor XII: evaluation and use for the measurement of factor XII levels in cardiopulmonary bypass patients. Thromb.Res.1999; 94: 103–9.
18.
ColmanRWSchmaierAH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood1997; 90: 3819–43.
19.
BevanDH. Cardiac bypass haemostasis: putting blood through the mill. Br.J.Haematol.1999; 104: 208–19.
20.
BoisclairMDLaneDAPhilippouHEsnoufMPSheikhSHuntBMechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood1993; 82: 3350–7.
21.
PixleyRAZellisSBankesPDeLa CadenaRAPageJDScottCFPrognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome. Crit Care Med.1995; 23: 41–51.
22.
KarlsrudTSBuoLAasenAOJohansenHT. Cleavage of plasma high molecular weight kininogen in surgical ICU patients. Intensive Care Med.1996; 22: 760–5.
23.
SalmonJCardiganRMackieICohenSLMachinSSingerM. Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med.1997; 23: 38–43.
24.
SchmaierAH. Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr.Opin.Hematol.2000; 7: 261–5.
25.
HeapMJRidleySAHodsonKMartosFJ. Are coagulation studies on blood sampled from arterial lines valid?Anaesthesia1997; 52: 640–5.
26.
AlzetaniAVohraHAPatelRL. Can we rely on arterial line sampling in performing activated plasma thromboplastin time after cardiac surgery?Eur.J.Anaesthesiol.2004; 21: 384–8.